LynkuetTM (elinzanetant) receives first global approval in UK for moderate to severe menopause-related hot flashes, based on OASIS trials. It's the first dual neurokinin-targeted therapy.
ST Engineering and NHG Health partner to co-develop engineering and smart systems, enhancing patient care and optimizing health service delivery for 1.5 million Singapore residents.
BlueRock’s OpCT-001, the first iPSC-derived therapy for photoreceptor diseases, enters Phase 1/2a CLARICO trial to assess safety and impact on vision loss.